Tirzepatide vs Semaglutide and the Pipeline
SURMOUNT-5 Head-to-Head, Oral Agents, and Retatrutide
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Tirzepatide & semaglutide approved; oral agents and retatrutide investigational/emerging
Reference only. Not medical advice.
What can go wrong
Higher-efficacy agents tend to carry the same GI-dominant adverse-event profile, often more pronounced during titration, and greater absolute weight loss intensifies the lean-mass and nutritional considerations. Retatrutide's glucagon-receptor component warrants attention to heart rate and metabolic parameters in ongoing trials. Oral agents have their own absorption and dosing-timing constraints (peptide oral semaglutide must be taken fasting).
This is something to take to a clinician. The Atlas can tell you what is known about tirzepatide vs semaglutide and the pipeline in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
SURMOUNT-5, a 72-week head-to-head randomized trial (published in NEJM, presented at the 2025 European Congress on Obesity), found tirzepatide produced greater weight loss than semaglutide: about 20.2% vs 13.7% mean reduction. The pipeline is advancing fast: oral GLP-1 orforglipron (ATTAIN-1, ~11-12% weight loss) and oral semaglutide (OASIS-4, ~13.6%) promise pill-based options, while the triple agonist retatrutide (TRIUMPH program) has shown weight loss up to roughly 30%, approaching bariatric-surgery territory.
The arms race that keeps raising the weight-loss ceiling.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
What people get wrong
Often saidAll GLP-1 drugs are equivalent
ActuallyHead-to-head SURMOUNT-5 showed tirzepatide produced meaningfully more weight loss than semaglutide.
Often saidPills can't match injections
ActuallyOral agents trail the best injectables on magnitude but are clinically meaningful and may expand access.
Who profits, and who pushes back
Open-label trial critics
SURMOUNT-5 was open-label, so unblinded patients and investigators may have influenced adherence, behavior, and reported outcomes, modestly inflating the apparent gap between agents.
Comparative-dosing skeptics
Differences partly reflect the agents' dosing ceilings and titration; a head-to-head at maximally tolerated doses does not fully separate intrinsic potency from how high each drug can be pushed.
Real-world effectiveness researchers
Tolerability, cost, insurance access, and discontinuation in practice can narrow the efficacy advantage seen in a controlled trial, so head-to-head percentages may not translate directly to typical patients.
Set against the alternatives
In SURMOUNT-5 (751 participants, 72 weeks, max tolerated doses), tirzepatide bested semaglutide: ~20.2% vs ~13.7% mean weight loss, with ~19.7% vs ~6.9% of participants losing >=30% of body weight, and greater waist-circumference reduction (~18.4 cm vs ~13.0 cm). Tirzepatide's dual GIP/GLP-1 mechanism is the leading explanation. The pipeline pushes further: triple agonist retatrutide adds glucagon-receptor agonism and has reached ~30% weight loss in phase 3.
| Agent | Mechanism | Weight loss (key trial) | Status |
|---|---|---|---|
| Semaglutide | GLP-1 | ~14.9% (STEP 1) / ~13.7% (SURMOUNT-5) | Approved |
| Tirzepatide | GIP + GLP-1 | ~21% (SURMOUNT-1) / ~20.2% (SURMOUNT-5) | Approved |
| Orforglipron | Oral GLP-1 (small molecule) | ~11-12% (ATTAIN-1) | Emerging/regulatory |
| Oral semaglutide 25mg | Oral GLP-1 (peptide) | ~13.6% (OASIS-4) | Emerging |
| Retatrutide | GIP + GLP-1 + glucagon | up to ~30% (TRIUMPH) | Investigational (phase 3) |
What we do not know
- Does tirzepatide's weight-loss edge translate into superior cardiovascular and mortality outcomes?
- How do the agents compare on long-term durability, weight regain, and lean-mass preservation?
- Will oral agents (orforglipron, oral semaglutide) match injectable efficacy in head-to-head trials?
- Can retatrutide's ~30% loss be sustained safely, and how does it compare directly to dual agonists?
- What is the comparative effect on testosterone and reproductive endpoints in men across these agents?
What could change
Oral GLP-1 agentsOrforglipron and oral semaglutide could broaden access by removing the injection barrierTriple agonistsRetatrutide (GLP-1/GIP/glucagon) is pushing weight loss toward bariatric-surgery levelsMuscle-preserving combinationsAgents and add-ons aimed at preserving lean mass during weight loss are in development
At a glance
- SURMOUNT-5 tirzepatide
- ~20.2% weight loss at 72 wks
- SURMOUNT-5 semaglutide
- ~13.7% weight loss at 72 wks
- Orforglipron (oral GLP-1, ATTAIN-1)
- ~11-12% weight loss
- Retatrutide (triple agonist, TRIUMPH)
- up to ~30% weight loss
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Tirzepatide vs Semaglutide and the Pipeline. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
SURMOUNT-5 (NEJM; ECO 2025)2025
Tirzepatide ~20.2% vs semaglutide ~13.7% mean weight loss at 72 weeks; tirzepatide superior across thresholds
ATTAIN-1 (orforglipron, NEJM)2025
Oral small-molecule GLP-1 produced ~11-12% mean weight loss over 72 weeks in adults with obesity
OASIS-4 (oral semaglutide 25mg)2025
~13.6% mean weight loss over 64 weeks
TRIUMPH program (retatrutide, triple agonist)2025-2026
Phase 3 results showed weight loss up to ~30%, approaching surgical magnitude